| Composition | Olmesartan Medoxomil 20mg Amlodipine 5mg Hydrochlorothiazide 12.5mg |
|---|---|
| Dosage | TABLET |
| Packing Size | 10×10 |
| Packing | Alu-Alu |
OLMIVIN AMH 20/5/12.5 is a triple-combination antihypertensive tablet that combines Olmesartan Medoxomil 20 mg, Amlodipine 5 mg, and Hydrochlorothiazide 12.5 mg. This formulation is specifically designed for patients whose blood pressure is not adequately controlled by monotherapy or dual therapy, offering potent and comprehensive blood pressure management.
By targeting three different mechanisms, OLMIVIN AMH provides effective hypertension control, reducing the risk of heart attack, stroke, and kidney complications.
Each tablet contains:
Olmesartan Medoxomil 20 mg – Angiotensin II receptor blocker that relaxes blood vessels, lowering blood pressure.
Amlodipine 5 mg – Calcium channel blocker that relaxes blood vessels and improves blood flow.
Hydrochlorothiazide 12.5 mg – Thiazide diuretic that reduces fluid retention, decreasing blood volume and pressure.
(Excipients q.s., as per approved formulation.)
Tablet
Antihypertensive / Triple Combination Therapy
OLMIVIN AMH 20/5/12.5 Tablets are indicated for:
Management of hypertension (high blood pressure)
Patients requiring triple therapy for optimal blood pressure control
Reduction of cardiovascular risk in patients with persistent hypertension
Prevention of hypertension-related complications, including heart attack, stroke, and kidney damage
Olmesartan Medoxomil blocks the angiotensin II receptor, causing vasodilation and reducing aldosterone-mediated sodium retention.
Amlodipine inhibits calcium influx in vascular smooth muscles, relaxing blood vessels and lowering vascular resistance.
Hydrochlorothiazide increases urinary excretion of sodium and water, reducing blood volume and pressure.
Together, the triple combination provides synergistic blood pressure control by addressing vascular resistance, fluid volume, and hormonal regulation.
Recommended Dose: As prescribed by the physician, usually once daily
Route: Oral
Duration: Long-term therapy as advised by a healthcare provider
Note: Regular monitoring of blood pressure, electrolytes, and kidney function is recommended during therapy.
Provides comprehensive blood pressure control
Reduces risk of heart attack, stroke, and kidney disease
Targets three different pathways for effective hypertension management
Convenient once-daily tablet improves patient adherence
Suitable for patients uncontrolled by monotherapy or dual therapy
OLMIVIN AMH 20/5/12.5 is generally well tolerated. Possible side effects include:
Dizziness or lightheadedness
Swelling of ankles or feet
Mild gastrointestinal discomfort
Electrolyte imbalances (rare)
Fatigue
Consult your physician if side effects persist or worsen.
Use with caution in renal or liver impairment
Avoid during pregnancy or lactation unless prescribed
Inform your doctor about other medications to prevent drug interactions
Regular monitoring of blood pressure, kidney function, and electrolytes is advised
Store below 25°C, in a dry place away from sunlight. Keep out of reach of children.
Brand Name: OLMIVIN AMH 20/5/12.5
Composition: Olmesartan Medoxomil 20 mg + Amlodipine 5 mg + Hydrochlorothiazide 12.5 mg
Dosage Form: Tablet
Therapeutic Class: Antihypertensive / Triple Combination Therapy
Manufacturer: [Insert Company Name]
Packaging: [Example: 10×10 Tablets / Strip]
Provides potent, triple-action blood pressure control
Reduces cardiovascular and renal risks associated with hypertension
Convenient once-daily dosing enhances compliance
Manufactured under strict GMP-certified quality standards
OLMIVIN AMH 20/5/12.5 (Olmesartan Medoxomil 20 mg + Amlodipine 5 mg + Hydrochlorothiazide 12.5 mg Tablets) delivers comprehensive blood pressure management for patients with resistant or uncontrolled hypertension. By targeting vascular resistance, fluid retention, and hormonal regulation, it helps prevent cardiovascular and renal complications while supporting long-term heart health.
